This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV (OPTI-NNRTI)

This study has been terminated.
(A delay in protocol approval and approval of laboratory sites in Salvador, Brazil left too little time for completion of enrollment into the study.)
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00523458
First received: August 29, 2007
Last updated: July 20, 2011
Last verified: July 2011
History of Changes
August 29, 2007
July 20, 2011
July 2007
March 2008   (Final data collection date for primary outcome measure)
Decline in HIV RNA in plasma Rise in CD4 cell count [ Time Frame: Baseline, and Weeks 8, 20 and 32 ]
These laboratory measures would be used to determine if there was a difference in the ARV failure rate between patients receiving standard dose vs high dose treatment with NNRTIs
Decline in HIV RNA in plasma Rise in CD4 cell count
Complete list of historical versions of study NCT00523458 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
Not Provided
Because drugs used to treat TB can reduce the amount of the anti-HIV drugs that reach the sites where the virus is located, this study is designed to see whether it is necessary to use higher doses of antiviral (anti-HIV) drugs while patients are receiving therapy with rifampin, one of the drugs commonly used to treat TB. Participants will be assigned to one of 4 arms (see below) and will be followed during the time when they are receiving both treatments.
This is an open label, randomized study with 4 arms: 1.) Standard dose and 2.) high dose nevirapine; and 3.) standard dose and 4.) high dose efavirenz. Subjects in all 4 arms will also receive 2 nucleoside analog drugs. Patients will have routine monitoring for the treatment of TB and HIV, as well as some additional blood samples to follow the virus in the blood and to determine the effect of the TB therapy on the amounts of anti-HIV drugs that are in the body.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • HIV Infections
  • Tuberculosis
Drug: efavirenz or nevirapine
Patients co-infected with HIV and TB will receive either "standard" doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or "high" doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin.
Other Names:
  • Sustiva (efavirenz)
  • Viramune (nevirapine)
  • Active Comparator: 1
    Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
    Intervention: Drug: efavirenz or nevirapine
  • Experimental: 2
    High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
    Intervention: Drug: efavirenz or nevirapine
  • Active Comparator: 3
    Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
    Intervention: Drug: efavirenz or nevirapine
  • Experimental: 4
    High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
    Intervention: Drug: efavirenz or nevirapine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
5
March 2008
March 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • ARV naïve subjects
  • Documented HIV infection
  • Documented TB infection
  • Platelet count 40,000/mm3
  • Hemoglobin ≥8.0 g/dL
  • Absolute neutrophil count (ANC) >500/mm3
  • AST (SGOT), ALT (SGPT), and alkaline phosphatase <3 X ULN
  • Total bilirubin <2.5 x ULN
  • Calculated creatinine clearance ≥60 mL/min
  • For women of reproductive potential, negative urine pregnancy test

Exclusion Criteria:

  • Unable to provide informed consent.
  • History drug abuse that the investigators suspect will interfere with compliance to study medications and visits.
  • Patients on hemodialysis.
  • Tuberculosis meningitis.
  • Women with CD4 > 250 and men with CD4 > 400 due to higher risk of hepatotoxicity related to use of NVP.
  • Positive serology for hepatitis C.
  • Evidence for active hepatitis B including positive serologies for HBsAg, HBeAg, or HBV-DNA. Note: If anti-HBs is positive, patient is eligible for study if liver enzymes are within the parameters indicated in the inclusion criteria
  • Women who are breast-feeding
  • Known allergy/sensitivity to study drug(s) or their formulations
  • Patients with other OIs or intercurrent illness that could affect their ability to take study drugs
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Brazil
 
 
NCT00523458
Stanford Protocol ID: 95564
Yes
Not Provided
Not Provided
Terrence F Blaschke, Principle Investigator, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Terrence F Blaschke, M.D. Stanford University
Stanford University
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP